Unbiased Analysis of Today's Healthcare Issues

Friday Links

Demoted in DC. Is big government not big enough? World’s most internationally revered money-laundering scam? Workers’ Comp golden rule. Bird flu in China.

Read the rest of this entry »

Friday Links

New hope for cancer treatment? Strategic drug filling around Medicare eligibility date. Unlearning descriptive statistics. Fighting antibiotic-resistant bacteria. Cost disease.

Read the rest of this entry »

Links

Cardiologists, oncologists decry travel ban Treating chronic illness. Pancreatic cancer breakthrough? Statins can treat cancer? Cancer screening and cost sharing. The problem of polypharmacy.

Read the rest of this entry »

Trump Links

In honor of inauguration day, some Trump-relevant links: “Art of the Deal” in health care Trump and speculative markets. On “repeal and replace” (with Wile E. Coyote graphic) Will Trump cut public health funding? Trump’s HHS appointee.

Read the rest of this entry »

Friday Links

Why your city has no money. The “words matter” HWR The AI poker player? Should anti-vaccine MDs lose their license? The dental-medical divide.

Read the rest of this entry »

Friday Links

Wine and breast cancer. The promise of molecular imaging. The world’s most expensive drug? Who will be the binding constraint for drug access? 7 stages of robot replacement.

Read the rest of this entry »

Last Links Post of 2016

A “shadowy crony group”? The real 2016 celebrity deaths. “The GOP isn’t going to repeal ACA.” Economists versus the Economy. Art of the Deal coming to Rx?

Read the rest of this entry »

Mid-week links

Unified theory of scarcity. Will price transparency cut costs? Potential. Surprise bills. Should academics partner with industry? Giannis!

Read the rest of this entry »

Friday Links

Does risk aversion change after a health shock. DCE vs. BWS. Does insurance cause high pharmaceutical prices? The latest developments in P4P. Drug prices rise, but ROI falls?

Read the rest of this entry »

Friday Links

CON laws don’t reduce mortality Why don’t people like pharma companies? Just give ‘em cash. Is value-based purchasing being undermined? Cancer drugs don’t live up to the hype?

Read the rest of this entry »